OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026
· prnewswire.com · popularity 19/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
— 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refractory NSCLC — — Preliminary efficacy and safety results support further development of cesalatamig monotherapy — ROCKVILLE, Md., Nov. 6,...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 9.